The table below shows Apellis Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$268.30M
$458.58M
$178.49M
$166.80M
$196.83M
$199.69M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$76.96M
$68.19M
$67.02M
$86.42M
$88.57M
$77.95M
APLS annual revenue (10-K history)
Apellis Pharmaceuticals, Inc. reported annual revenue of $1.00B for fiscal year 2025. That is up 28.5% from $781.37M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $250.65M (FY 2020) to $1.00B. Figures come from the company's audited annual reports as filed with the SEC.